Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells

Cells
doi 10.3390/cells8121480
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

“Epigenetic” Modification as Therapy for Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2017English

Awareness of Emerging Novel Epigenetic Targeting Therapy in Acute Myeloid Leukemia

Cancer therapy & Oncology International Journal
2018English

Epigenetic Therapy Combinations in Acute Myeloid Leukemia: What Are the Options?

Therapeutic Advances in Hematology
Hematology
2019English

Increased Anti-Leukemic Activity of Decitabine via AR-42-induced Upregulation of miR-29b: A Novel Epigenetic-Targeting Approach in Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

The Epigenetic Landscape of Acute Myeloid Leukemia

Advances in Hematology
Hematology
2014English

Pharmacokinetics and Pharmacodynamics of Suberoylanilide Hydroxamic Acid in Cats

Journal of Veterinary Pharmacology and Therapeutics
VeterinaryPharmacology
2013English

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

PLoS ONE
Multidisciplinary
2010English

Therapy of Acute Myeloid Leukemia

2012English

Suberoylanilide Hydroxamic Acid Induces Limited Changes in the Transcriptome of Primary CD4+ T Cells

AIDS
Infectious DiseasesAllergyImmunology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy